Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2018.
Commission
File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation
of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ]
Form 40-F [
]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ___
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ___
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's “home country”), or under the rules of the
home country exchange on which the registrant's securities are
traded, as long as the report or other document is not a press
release, is not required to be and has not been distributed to the
registrant's security holders, and, if discussing a material event,
has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Intellipharmaceutics
International Inc. (the “Company”) has (i) instructed
American Stock Transfer & Trust Company, LLC to send a notice
to holders of the warrants issued by the Company on or after June
2, 2016 in connection with that certain Underwriting Agreement
between the Company and Dawson James Securities, Inc., dated May
27, 2016, and (ii) sent a notice to holders of other outstanding
warrants to acquire common shares of the Company, informing them of
certain adjustments resulting from the recent one-for-10 reverse
split of common shares of the Company previously reported on the
Company’s Form 6-K filed with the Securities and Exchange
Commission on September 13, 2018. A copy of each such notice is
attached at Exhibits 99.1 through 99.7 to this report and
incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International Inc.
(Registrant)
/s/ Andrew Patient
|
|
Date:
September 21, 2018
|
Andrew
Patient
Chief Financial Officer
|
EXHIBIT LIST
|
Exhibit
|
Description
|
|
99.1
|
Form of
Notice to Warrant Holders pursuant to that certain Underwriting
Agreement by and between the Company and Dawson James Securities,
Inc., dated May 27, 2016
|
|
99.2
|
Form of
Notice to Warrant Holders pursuant to that certain Engagement
Agreement by and between the Company and H.C. Wainwright & Co.,
LLC, dated October 10, 2017
|
|
99.3
|
Form of
Notice to Warrant Holders pursuant to that certain Securities
Purchase Agreement by and among the Company and the purchasers
named therein, dated October 11, 2017
|
|
99.4
|
Form of
Notice to Warrant Holders pursuant to that certain Engagement
Letter by and between the Company and H.C. Wainwright & Co.,
LLC, dated March 12, 2018
|
|
99.5
|
Form of
Notice to Warrant Holders pursuant to that certain Securities
Purchase Agreement by and among the Company and the purchasers
named therein, dated March 13, 2018
|
|
99.6
|
Form of
Notice to Warrant Holders pursuant to that certain Engagement
Letter by and between the Company and H.C. Wainwright & Co.,
LLC, dated March 18, 2018
|
|
99.7
|
Form of
Notice to Warrant Holders pursuant to that certain Securities
Purchase Agreement by and among the Company and the purchasers
named therein, dated March 19, 2018
|